Potent ATM kinase inhibitor (IC50
= 6.3 nM). Exhibits little to no nonspecific target effects against a panel of 229 protein kinases; displays similar target selectivity to KU 55933
(Cat. No. 3544). Inhibits migration and invasion of human glioma cells in vitro
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Sold with the permission of AstraZeneca.
Improved ATM kinase inhibitor KU-60019 radiosensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasion.
Golding et al.
Mol.Cancer Ther., 2009;8:2894
The citations listed below are publications that use Tocris products. Selected citations for KU 60019 include:
Showing Results 1 - 8 of 8